# A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

> **NCT01460940** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Adult Nodular Sclerosis Hodgkin Lymphoma
- Recurrent Adult Hodgkin Lymphoma

## Interventions

- **DRUG:** panobinostat
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT01460940
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-13
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460940, "A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01460940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*